Amneal Pharmaceuticals, Inc. AMRX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.05B+0.9% | $3.02B+2.9% | $2.93B+2.9% | $2.85B+0.8% | $2.83B+1.3% | ||
| $1.87B-1.9% | $1.91B+2.7% | $1.86B+4.4% | $1.78B-0.8% | $1.79B+1.0% | ||
| $1.18B+5.8% | $1.11B+3.2% | $1.08B+0.4% | $1.07B+3.5% | $1.04B+1.7% | ||
| 38.7%+1.8pp | 36.9%+0.1pp | 36.8%-0.9pp | 37.7%+1.0pp | 36.7%+0.2pp | ||
| $184.52M-0.9% | $186.18M-9.5% | $205.62M+1.1% | $203.37M+6.2% | $191.46M+0.4% | ||
| $547.4M+3.9% | $526.83M+3.5% | $509.06M+3.9% | $489.93M+1.6% | $482.13M+1.2% | ||
| —— | —— | —— | —— | —— | ||
| $7.06M+34.7% | $5.24M0.0% | $5.24M-14.8% | $6.15M0.0% | $6.15M+562% | ||
| $435.52M+10.5% | $394.1M+10.1% | $357.86M-4.9% | $376.32M+4.4% | $360.42M+44.6% | ||
| 14.3%+1.2pp | 13.1%+0.9pp | 12.2%-1.0pp | 13.2%+0.5pp | 12.7%+3.8pp | ||
| -$237.51M+1.5% | -$241.09M+2.2% | -$246.52M+1.1% | -$249.21M+0.2% | -$249.83M+3.4% | ||
| -$253.62M+0.5% | -$254.89M+11.9% | -$289.2M-0.8% | -$287.02M+5.1% | -$302.42M+0.6% | ||
| —— | —— | —— | —— | —— | ||
| $181.9M+30.7% | $139.21M+103% | $68.66M-23.1% | $89.3M+54.0% | $58M+205% | ||
| $584K-94.8% | $11.28M+2.2% | $11.04M-71.0% | $38.06M+48.8% | $25.58M+35.6% | ||
| $122.12M+69.5% | $72.06M+1,121% | $5.9M+74.8% | $3.38M+126% | -$13.05M+88.8% | ||
| 4%+1.6pp | 2.4%+2.2pp | 0.2%+0.1pp | 0.1%+0.6pp | -0.5%+3.7pp | ||
| $0.38+65.2% | $0.23+1,050% | $0.02+100.0% | $0.01+125% | -$0.04+89.5% | ||
| $0.39+69.6% | $0.23+1,050% | $0.02+100.0% | $0.01+125% | -$0.04+89.5% | ||
| 1.3B+0.4% | 1.3B+1.2% | 1.3B+1.2% | 1.3B+0.3% | 1.3B+1.3% | ||
| 1.3B+0.4% | 1.3B+0.4% | 1.2B+0.4% | 1.2B+0.4% | 1.2B+0.3% | ||
| -$304K-178% | $390K+128% | -$1.39M-12.0% | -$1.24M+46.7% | -$2.33M+97.6% | ||
| $6.43M+198% | -$6.59M+63.9% | -$18.26M+63.8% | -$50.4M+15.2% | -$59.42M-17.2% | ||
| -$237.51M+1.5% | -$241.09M+2.2% | -$246.52M+1.1% | -$249.21M+0.2% | -$249.83M+3.4% | ||
| —— | —— | $1.41M-80.2% | $7.12M+608% | -$1.4M+79.5% | ||
| $7.41M-2.9% | $7.63M-5.5% | $8.07M+6.2% | $7.6M+14.7% | $6.63M+13.4% | ||
| $16.75M+1.4% | $16.52M+199% | $5.53M+1.0% | $5.47M-33.5% | $8.23M-30.2% | ||
| $7.06M+34.7% | $5.24M0.0% | $5.24M-14.8% | $6.15M0.0% | $6.15M+562% | ||
| $3.05B+0.9% | $3.02B+2.9% | $2.93B+2.9% | $2.85B+0.8% | $2.83B+1.3% | ||
| $435.52M+10.5% | $394.1M+10.1% | $357.86M-4.9% | $376.32M+4.4% | $360.42M+44.6% | ||
| $435.52M+10.5% | $394.1M+10.1% | $357.86M-4.9% | $376.32M+4.4% | $360.42M+44.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $3.0B in revenue over the trailing twelve months, up 7.6% year over year.
- Is Amneal Pharmaceuticals, Inc. profitable?
- Amneal Pharmaceuticals, Inc. reported $122.1M in net income over the trailing twelve months, a 4.0% net margin.
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.
- What is Amneal Pharmaceuticals, Inc.'s earnings per share?
- Amneal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $0.38.
- Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
